Democratic leaders unveil economic agenda

AHA News Now

Senate Democratic Leader Charles Schumer and House Democratic Leader Nancy Pelosi today unveiled an economic plan focused on improving wages, lowering costs and boosting job opportunities. To lower the cost of prescription drugs, the plan calls for creating a new agency to investigate and take action... read more

Topic: Advocacy and Public Policy
Tags: Medicare, drug prices

CMS releases 2018 OPPS/ASC proposed rule

AHA News Now

The Centers for Medicare & Medicaid Services today proposed to update hospital outpatient prospective payment system rates by 1.75% in calendar year 2018 compared to CY 2017. The rule also would drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing Program. Specifically,... read more

Topic: Advocacy and Public Policy
Tags: 340B, quality, physicians, site neutral payment, Medicare, rural, Critical Access Hospitals, regulation, drug prices

MedPAC issues June report to Congress

AHA News Now

The Medicare Payment Advisory Commission yesterday released its June report to Congress, which includes the panel’s recent recommendations for reforming Medicare payment for Part B drugs and accelerating the roll out of a post-acute care prospective payment system. The report also discusses possible... read more

Topic: Advocacy and Public Policy
Tags: physicians, Medicare, rural, emergency care, drug prices

AHA urges Congress to address rising cost of drugs

AHA News Now

The AHA today urged Congress and the administration to take immediate action to rein in the rising cost of drugs. In a statement submitted to the Senate Committee on Health, Education, Labor and Pensions for a hearing on the issue, AHA offered specific recommendations to increase competition, innovation... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Reining in drug prices

Blog

A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.

In a statement submitted to the... read more

Topic: Advocacy and Public Policy
Tag: drug prices

HRSA delays until Oct. 1 the effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January. “The additional time provided to the public before the rule... read more

Topic: Advocacy and Public Policy
Tags: 340B, regulation, drug prices

Poll: Lowering prescription drug costs a high priority for many Americans

AHA News Now

Six in 10 Americans identify lowering the cost of prescription drugs as a “top priority” for President Trump and Congress when it comes to health care, according to a recent poll by the Kaiser Family Foundation. When asked about specific proposals to hold down drug costs, a majority of adults support... read more

Topic: Advocacy and Public Policy
Tags: Medicare, drug prices

Legislation to encourage generic drug entry introduced in House and Senate

AHA News Now

Sen. Patrick Leahy (D-VT) and other members of the Senate and House Judiciary committees today introduced the Creating and Restoring Equal Access to Equivalent Samples Act, which targets anticompetitive behaviors used to block and delay entry of generic drugs. Among other provisions, the bipartisan... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Hearings highlight how restrictive use programs can limit generic competition

AHA News Now

A subcommittee of the House Oversight and Government Reform Committee today held a hearing to examine how drug makers may misuse voluntary restricted distribution systems to delay or block generic competition. Janet Woodcock, M.D., director of the Food and Drug Administration’s Center for Drug Evaluation... read more

Topic: Advocacy and Public Policy
Tag: drug prices

HRSA further delays effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation, drug prices

Keyword Search

Date